Compare VRTX & INTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRTX | INTU |
|---|---|---|
| Founded | 1989 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Computer Software: Prepackaged Software |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7B | 102.8B |
| IPO Year | 2006 | 1996 |
| Metric | VRTX | INTU |
|---|---|---|
| Price | $450.98 | $281.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 29 | 20 |
| Target Price | $539.69 | ★ $692.35 |
| AVG Volume (30 Days) | 1.2M | ★ 6.4M |
| Earning Date | 05-04-2026 | 05-21-2026 |
| Dividend Yield | N/A | ★ 1.22% |
| EPS Growth | ★ 836.54 | 31.06 |
| EPS | 4.02 | ★ 15.05 |
| Revenue | $2,488,652,000.00 | ★ $18,831,000,000.00 |
| Revenue This Year | $10.79 | $15.03 |
| Revenue Next Year | $10.47 | $12.41 |
| P/E Ratio | $112.05 | ★ $18.71 |
| Revenue Growth | ★ 46.20 | 15.63 |
| 52 Week Low | $362.50 | $268.01 |
| 52 Week High | $509.98 | $813.48 |
| Indicator | VRTX | INTU |
|---|---|---|
| Relative Strength Index (RSI) | 58.17 | 34.62 |
| Support Level | $449.40 | N/A |
| Resistance Level | $464.15 | $420.38 |
| Average True Range (ATR) | 10.50 | 14.65 |
| MACD | 1.23 | -2.27 |
| Stochastic Oscillator | 95.57 | 13.68 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Intuit serves small and midsize businesses with accounting software QuickBooks and online marketing platform Mailchimp. The company also operates retail tax filing tool TurboTax, personal finance platform Credit Karma, and a suite of professional tax offerings for accountants. Founded in the mid-1980s, Intuit enjoys a dominant market share for small-to-midsize business accounting and self-serve tax filing in the US.